Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
grade F 24.75 0.04% 0.01
MYGN closed up 0.04 percent on Monday, November 18, 2019, on 72 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical MYGN trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Narrow Range Bar Range Contraction 0.04%
Wide Bands Range Expansion 0.04%

Older signals for MYGN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Ovarian Cancer Medical Genetics Diagnostic Tests Pancreatic Cancer Biomarkers Chemical Pathology Personalized Medicine
Is MYGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 19 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MO, MYGN and YJ
Nov 18 SHAREHOLDER ALERT: SNDL WTRH MYGN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Nov 18 INVESTOR ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: November 26, 2019
Nov 18 CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, OSTK, MTCH
Nov 18 8-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching
Nov 17 CLASS ACTION UPDATE for SEE, COF and MYGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Nov 16 CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, COF, MTCH
Nov 15 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PUMP, MYGN and UA
Nov 15 Myriad Genetics, Inc. (MYGN),, Inc. (OSTK) & Waitr Holdings Inc. (WTRH) - Bronstein, Gewirtz & Grossman, LLC Class Action Announcement
Nov 15 IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
See more MYGN news...
Indicator Value
52 Week High 48.4
52 Week Low 20.1
Average Volume 1,183,986
200-Day Moving Average 29.2404
50-Day Moving Average 28.6304
20-Day Moving Average 28.4715
10-Day Moving Average 23.786
Average True Range 1.6327
ADX 37.0
+DI 19.0798
-DI 34.3154
Chandelier Exit (Long, 3 ATRs ) 30.3919
Chandelier Exit (Short, 3 ATRs ) 24.9981
Upper Bollinger Band 38.052
Lower Bollinger Band 18.891
Percent B (%b) 0.31
BandWidth 67.298878
MACD Line -1.6056
MACD Signal Line -1.1131
MACD Histogram -0.4925
Fundamentals Value
Market Cap 1.7 Billion
Num Shares 68.6 Million
EPS 0.32
Price-to-Earnings (P/E) Ratio 77.34
Price-to-Sales 3.01
Price-to-Book 2.98
PEG Ratio 3.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.97
Resistance 3 (R3) 26.05 25.72 25.76
Resistance 2 (R2) 25.72 25.41 25.68 25.69
Resistance 1 (R1) 25.24 25.22 25.08 25.16 25.63
Pivot Point 24.91 24.91 24.83 24.87 24.91
Support 1 (S1) 24.43 24.60 24.27 24.35 23.87
Support 2 (S2) 24.10 24.41 24.06 23.81
Support 3 (S3) 23.62 24.10 23.74
Support 4 (S4) 23.54